Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of pulmonary IL-21 expression during latent TB and M. tuberculosis/SIV coinfection.

JCI insight·2026
Same author

Work challenges and cancer-related cognitive impairment: level of education accounts for unmet needs beyond cognitive impairment severity.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Depression, psychological distress, and coping strategies among African migrants in Australia: a cross-sectional web-based study.

BMC psychiatry·2025
Same author

Neurodegeneration Through the Lens of Bioinformatics Approaches: Computational Mechanisms of Protein Misfolding.

International journal of molecular sciences·2025
Same author

A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.

Healthcare (Basel, Switzerland)·2025
Same author

A primer on meta-awareness of mind wandering in schizotypy and schizophrenia.

Psychological research·2025
Same journal

Voices of Stroke Survivors With Dysphagia: A Roy Adaptation Model-Based Qualitative Analysis.

Brain and behavior·2026
Same journal

Korean Red Ginseng Attenuates Dysfunctions and Modulates Inflammatory and Neuroplasticity Markers in the Harmaline-Induced Model of Essential Tremor.

Brain and behavior·2026
Same journal

Pseudohallucination and Pilocytic Astrocytoma in the Pons.

Brain and behavior·2026
Same journal

Volume Alterations in Thalamic Subnuclei in Parkinson's Disease Dementia and Machine Learning-Based Prediction of Diagnosis and Severity.

Brain and behavior·2026
Same journal

ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.

Brain and behavior·2026
Same journal

The "Brain's Traffic Map" Reveals Neural Pathways Linked to Coronary Microvascular Dysfunction in Women.

Brain and behavior·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 25, 2010

Functional and Clinical: An Explainable Deep Learning Model for Multimodal Alzheimer's Disease Classification.

Samuel L Warren1, Ahmed A Moustafa1,2

  • 1School of Psychology, Faculty of Society and Design, Bond University, Gold Coast, Queensland, Australia.

Brain and Behavior
|January 30, 2026
PubMed
Summary
This summary is machine-generated.

Combining functional magnetic resonance imaging (fMRI) with clinical data significantly improves Alzheimer's disease (AD) classification using deep learning. This multimodal approach enhances model accuracy and explainability for better clinical application.

Keywords:
Alzheimer's disease (AD)clinical datadeep learningdefault mode network (DMN)explainable artificial intelligence (XAI)functional magnetic resonance imaging (fMRI)

More Related Videos

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Related Experiment Videos

Last Updated: Jun 19, 2026

Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 25, 2010

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Area of Science:

  • Neuroimaging
  • Artificial Intelligence
  • Clinical Diagnostics

Background:

  • Deep learning models using fMRI show promise for Alzheimer's disease (AD) classification.
  • Challenges include small datasets, lack of explainability, and reliability issues like data leakage, hindering clinical adoption.

Purpose of the Study:

  • To develop a reliable and explainable multimodal deep learning model for AD classification.
  • To address limitations of fMRI-based models by integrating clinical data and employing explainable AI (XAI).

Main Methods:

  • A 3D convolutional neural network was trained on fMRI data from the default mode network and five clinical tests.
  • Multimodal data integration and a strict leave-one-out cross-validation were used to overcome data limitations and prevent data leakage.
  • Perturbation ranking was applied for feature importance analysis.

Main Results:

  • The multimodal model achieved 90% accuracy in classifying AD from controls, significantly outperforming models using only fMRI (58% accuracy).
  • Feature importance varied by diagnostic group, with clinical tests like the MoCA showing differential relevance for controls versus AD patients.
  • Explainable AI revealed distinct patterns of feature importance across clinical and fMRI data.

Conclusions:

  • Combining fMRI and clinical data in a multimodal deep learning model enhances AD classification accuracy and provides insights into disease characteristics.
  • The developed model demonstrates potential for refining diagnostic tools for Alzheimer's disease.
  • Further external validation with larger sample sizes is recommended.